GlassScriptPhysician profile
Amanda J Brown
NPI 1992945869
$5,813.74
in general payments reported to CMS, 2019-2025
20 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $289 · 2021: $375 · 2022: $770 · 2023: $1,227 · 2024: $1,057 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,275.56 | 2019-2025 | Precision 1, Eysuvis, Dailies |
| Coopervision INC. | $1,026.67 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $286.84 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $280.22 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $244.37 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $217.98 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $205.70 | 2019-2021 | |
| Abbvie INC. | $194.95 | 2023-2025 | Vuity, Lumigan |
| Allergan, INC. | $169.52 | 2019-2022 | |
| Rxsight INC | $140.53 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Glaukos Corporation | $132.45 | 2024 | |
| Dompe US, INC. | $122.79 | 2025 | Oxervate |
| Shire North American Group INC | $117.88 | 2019 | |
| Oyster Point Pharma, INC. | $91.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $81.43 | 2021-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $70.50 | 2025 | |
| Abb Con-Cise Optical Group LLC | $60.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $49.85 | 2024 | |
| Kala Pharmaceuticals, INC. | $24.44 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.